• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Enovis Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/19/26 4:54:13 PM ET
    $ENOV
    Industrial Specialties
    Health Care
    Get the next $ENOV alert in real time by email
    false 0001420800 0001420800 2026-05-19 2026-05-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 19, 2026

     

     

     

    Enovis Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-34045   54-1887631

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    2711 Centerville Road, Suite 400

    Wilmington, DE 19808

    (Address of principal executive offices) (Zip Code)

     

    (302) 252-9160

    (Registrant’s telephone number, including area code)

     

    Not applicable

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   ENOV   New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Approval of an Amendment to the Enovis Corporation 2020 Omnibus Incentive Plan

     

    At the Annual Meeting of Stockholders of Enovis Corporation (the “Company”) held on May 19, 2026 (the “Annual Meeting”), the Company’s stockholders voted on and approved an amendment to the Company’s 2020 Omnibus Incentive Plan (the “2020 Plan Amendment”). The 2020 Plan Amendment was previously adopted by the Company’s Board of Directors (the “Board”) on March 31, 2026, subject to the approval of the Company’s stockholders.

     

    The 2020 Plan Amendment (i) authorizes an additional 3,650,000 shares of the Company’s common stock, par value $0.001 per share, for issuance under the 2020 Omnibus Incentive Plan and (ii) increases the maximum aggregate dollar value of equity-based awards and cash compensation that may be granted to any Outside Director (as defined in the 2020 Plan) during any calendar year from $350,000 to $750,000; provided however, that in the calendar year in which an Outside Director is newly-elected or appointed director or newly-designated as lead director or chair, the maximum aggregate dollar value of equity-based and cash compensation granted to the Outside Director may be up to two hundred percent (200%) of the foregoing limit. The additional shares of common stock authorized to be issued under the 2020 Omnibus Incentive Plan pursuant to the 2020 Plan Amendment will be registered pursuant to a registration statement on Form S-8.

     

    A description of the 2020 Omnibus Incentive Plan, as amended, is set forth in the Company’s definitive proxy statement for the Annual Meeting, which was filed with the U.S. Securities and Exchange Commission on April 6, 2026 (the “Proxy Statement”) in the section entitled “Proposal 4: Approval of an amendment to the Enovis Corporation 2020 Omnibus Incentive Plan,” which description is incorporated herein by reference.

     

    The foregoing description of the 2020 Plan Amendment is qualified by the full text of the 2020 Plan Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On May 19, 2026, the Company held its Annual Meeting, at which five proposals were submitted to the Company’s stockholders. The proposals are described in detail in the Proxy Statement. The final results for each proposal are set forth below:

     

    Proposal 1- Election of Directors:

     

    The Company’s stockholders elected ten directors to the Board (to hold office until the next annual meeting of stockholders and until their respective successors are elected and qualified). The votes regarding this proposal were as follows:

     

    Nominee   For   Against   Abstain   Broker Non-Votes
    Barbara W. Bodem   51,537,774   226,376   14,689   2,032,985
    Liam J. Kelly   51,552,655   213,001   13,183   2,032,985
    Angela S. Lalor   51,269,131   495,519   14,189   2,032,985
    Damien McDonald   51,222,667   545,650   10,522   2,032,985
    Philip A. Okala   51,540,973   223,651   14,215   2,032,985
    Christine Ortiz   51,552,061   207,769   19,009   2,032,985
    A. Clayton Perfall   50,959,268   805,763   13,808   2,032,985
    Brady Shirley   50,994,745   773,196   10,898   2,032,985
    Rajiv Vinnakota   51,206,665   557,399   14,775   2,032,985
    Sharon Wienbar   51,553,287   209,586   15,966   2,032,985

     

     
     

     

    Proposal 2- Ratification of appointment of independent registered accounting firm:

     

    The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The votes regarding this proposal were as follows:

     

    For   Against   Abstain
    52,862,698   927,580   21,546

     

    Proposal 3- Advisory vote on the executive compensation of the named executive officers:

     

    The Company’s stockholders approved, by non-binding advisory vote, the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows:

     

    For   Against   Abstain   Broker Non-Votes
    49,531,111   2,175,335   72,393   2,032,985

     

    Proposal 4- Approve an amendment to the Enovis Corporation 2020 Omnibus Incentive Plan:

     

    The Company’s stockholders approved an amendment to the Enovis Corporation 2020 Omnibus Incentive Plan. The votes regarding this proposal were as follows:

     

    For   Against   Abstain   Broker Non-Votes
    50,391,554   1,295,073   92,212   2,032,985

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    10.1 Third Amendment to Enovis Corporation 2020 Omnibus Incentive Plan
       
    104 Cover Page Interactive Data File – The cover page from this Current Report on Form 8-K is formatted in Inline XBRL

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 19, 2026

     

      ENOVIS CORPORATION
         
      By: /s/ Bradley J. Tandy
      Name: Bradley J. Tandy
      Title: Senior Vice President and
        Chief Legal Officer

     

     

    Get the next $ENOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENOV

    DatePrice TargetRatingAnalyst
    4/17/2026Outperform
    William Blair
    1/6/2026$41.00Buy
    BTIG Research
    10/3/2024$62.00Mkt Outperform
    JMP Securities
    6/13/2024$53.00Neutral
    JP Morgan
    2/13/2024$72.00Overweight
    Stephens
    1/22/2024$75.00Buy
    UBS
    1/3/2024Outperform
    William Blair
    12/15/2023$62.00 → $70.00Buy
    Needham
    More analyst ratings

    $ENOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enovis Announces First Quarter 2026 Results

    First-quarter sales growth of 5% on a reported basisFirst-quarter Reconstructive sales grew 11% on a reported basisReiterating full-year 2026 revenue, adjusted EBITDA, adjusted EPS, and Free Cash Flow Conversion guidance Dallas, TX, May 07, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 3, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2026 Financial Results Enovis' first-quarter net sales of $589 million grew 5% on a reported basis and 3

    5/7/26 6:01:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis to Host First Quarter 2026 Results Conference Call on May 7th

    Dallas, TX, April 10, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2026 financial results on Thursday, May 7th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (800) 715-987

    4/10/26 8:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

    Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Fourth Quarter 2025 Financial Results Enovis' fo

    2/26/26 6:33:37 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    SEC Filings

    View All

    SEC Form SD filed by Enovis Corporation

    SD - Enovis CORP (0001420800) (Filer)

    5/28/26 5:21:46 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form S-8 filed by Enovis Corporation

    S-8 - Enovis CORP (0001420800) (Filer)

    5/19/26 4:57:30 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Enovis CORP (0001420800) (Filer)

    5/19/26 4:54:13 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Administrative Officer Engert Oliver bought $22,220 worth of shares (1,000 units at $22.22), increasing direct ownership by 2% to 49,640 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    6/3/26 9:00:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Director Shirley Brady was granted 9,346 shares, increasing direct ownership by 9% to 110,589 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    5/21/26 8:30:14 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Director Lalor Angela S was granted 9,346 shares, increasing direct ownership by 42% to 31,486 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    5/21/26 8:30:08 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Administrative Officer Engert Oliver bought $22,220 worth of shares (1,000 units at $22.22), increasing direct ownership by 2% to 49,640 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    6/3/26 9:00:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Chief Administrative Officer Engert Oliver bought $23,740 worth of shares (1,000 units at $23.74), increasing direct ownership by 2% to 48,640 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    3/16/26 9:00:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Chief Administrative Officer Engert Oliver bought $23,930 worth of shares (1,000 units at $23.93), increasing direct ownership by 2% to 47,640 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    3/12/26 7:35:49 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair resumed coverage on Enovis Corporation

    William Blair resumed coverage of Enovis Corporation with a rating of Outperform

    4/17/26 8:10:50 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    BTIG Research initiated coverage on Enovis Corporation with a new price target

    BTIG Research initiated coverage of Enovis Corporation with a rating of Buy and set a new price target of $41.00

    1/6/26 8:55:57 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    JMP Securities initiated coverage on Enovis Corporation with a new price target

    JMP Securities initiated coverage of Enovis Corporation with a rating of Mkt Outperform and set a new price target of $62.00

    10/3/24 7:29:21 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Leadership Updates

    Live Leadership Updates

    View All

    Enovis Appoints Oliver Engert as Chief Administrative Officer

    Dallas, TX, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology company, has announced that Oliver Engert has been appointed Chief Administrative Officer, effective today. In this newly-created role, Oliver will be responsible for leading Enovis' strategy development, driving organizational efficiency and enhancing operational excellence to support the company in its next phase of profitable, capital-efficient growth. Damien McDonald, CEO of Enovis said, "Oliver's appointment comes at a very exciting time for Enovis. As we take steps to build on our strong foundation and unlock our future potential, his extensive knowledge, skills a

    1/5/26 4:15:00 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

    Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

    4/2/25 6:30:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

    NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index

    1/7/25 6:19:00 PM ET
    $ARCH
    $CART
    $CEIX
    Coal Mining
    Energy
    Real Estate
    Industrial Specialties

    $ENOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Enovis Corporation

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    11/14/24 1:28:31 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    4/5/24 12:21:51 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    2/14/24 10:04:36 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Financials

    Live finance-specific insights

    View All

    Enovis Announces First Quarter 2026 Results

    First-quarter sales growth of 5% on a reported basisFirst-quarter Reconstructive sales grew 11% on a reported basisReiterating full-year 2026 revenue, adjusted EBITDA, adjusted EPS, and Free Cash Flow Conversion guidance Dallas, TX, May 07, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 3, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2026 Financial Results Enovis' first-quarter net sales of $589 million grew 5% on a reported basis and 3

    5/7/26 6:01:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis to Host First Quarter 2026 Results Conference Call on May 7th

    Dallas, TX, April 10, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2026 financial results on Thursday, May 7th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (800) 715-987

    4/10/26 8:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

    Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Fourth Quarter 2025 Financial Results Enovis' fo

    2/26/26 6:33:37 AM ET
    $ENOV
    Industrial Specialties
    Health Care